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Abstract. – OBJECTIVE: Osteopenia is a chro-
nic bone condition characterized by decreased 
calcification, density, or bone mass that, if untre-
ated, can lead to osteoporosis and bone fractu-
res. Although its increasing prevalence, nowa-
days osteopenia is not adequately prevented and 
managed. In this study, we evaluated the efficacy, 
in term of changes in bone density, and safety of 
an oral formulation based on turmeric phytoso-
me (Meriva®), in subjects suffering from low bo-
ne density. 
PATIENTS AND METHODS: 57 otherwise he-
althy subjects with low bone density were en-
rolled in this pilot, supplement study. Informed 
participants freely decided to follow either a 
standard management (SM) to control low bone 
density (control group=28) or SM associated 
with a curcumin-based oral supplementation 
(supplement group=29). The bone densities of 
heel, small finger and upper jaw were evaluated 
at inclusion and at different time points during 
the observational period (4, 12 and 24 weeks), in 
all subjects.
RESULTS: The bone density of the heel mea-
sured by the Sahara densitometer remarkably 
improved in the Meriva®-supplemented group, 
with a significant decrease of ultrasounds trans-
mission values at week 12 (-18.4%) and at week 
24 (-21.0%), compared with baseline values. The 
bone densities of small finger and upper jaw 
also significantly increased during the study 
in supplemented subjects, reaching +7.1% and 
+4.8%, respectively, at week 24, with respect to 
values at inclusion. Noteworthy, no significant 
changes of heel, small finger and upper jaw den-
sities were observed in the control group. Last, 
no safety and tolerability issues were reported 
during the observational period.
CONCLUSIONS: This preliminary study sug-
gests that a curcumin-based supplementation in 
combination with an appropriate lifestyle could 
be beneficial in the prevention and management 
of osteopenia.   
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Introduction
Osteopenia (low bone density) is a chronic 
bone condition characterized by decreased cal-
cification, density, or bone mass1; the progressive 
loss of bone can eventually lead to osteoporosis 
and fractures if unrecognized and untreated. 
Most cases of low bone density occur in aged 
subjects, particularly postmenopausal women2; 
indeed, a decline of estrogen levels in females 
at menopause or estrogens and androgens in 
males later in life leads to loss of bone mass and 
strength and contributes to the development of 
bone diseases such as osteopenia and osteoporo-
sis3. Nowadays, the increased risk of fracture is 
being diagnosed by Dual Energy X-ray Absorp-
tiometry (DXA), which assesses the amount of 
mineralized bone in the skeleton (bone mineral 
density, BMD)4. According to the World Health 
Organization (WHO) criteria based on DXA 
measurements, patients are considered having 
low bone mass (osteopenic), when their BMD 
t-score of the spine or hip ranges between -1 
and -2.5, whereas osteoporosis subjects have a 
t-score of -2.5 or lower5. Noteworthy, the ma-
jority of fractures occur in women whose BMD 
European Review for Medical and Pharmacological Sciences 2017; 21: 1684-1689
A. RIVA1, S. TOGNI1, L. GIACOMELLI2, F. FRANCESCHI1, R. EGGENHOFFNER2, 
B. FERAGALLI3, G. BELCARO3, M. CACCHIO3, H. SHU3, M. DUGALL3 
1Indena SpA, Milan, Italy.
2Department of Surgical Sciences and Integrated Diagnostics, School of Medicine,
 Genoa University, Genoa, Italy.
3Department of Medicine and Biotechnological Sciences, Irvine3 Labs, Chieti-Pescara University, 
 Pescara, Italy.
Corresponding Author:  Antonella Riva, MD; e-mail: antonella.riva@indena.com
Effects of a curcumin-based 
supplementation in asymptomatic subjects
with low bone density:
a preliminary 24-week supplement study
Curcumin-based supplementation in osteopenia
1685
scores are within the osteopenic, and not osteo-
porotic, range. From an analysis of the National 
Osteoporosis Risk Assessment (NORA) study 
database including 200,160 postmenopausal 
women who had no prior diagnosis of osteo-
porosis6, emerged that the number of subjects 
at risk of fractures is much higher in the os-
teopenic range due to the Gaussian distribution 
of BMD values in the population7. The lifetime 
risk of hip fracture, the most disabling one, is 
around 17.5% in white women and 6.0% in men 
in the US8, whereas is estimated at 11.4%, and 
3.1% for women and men, aged 50 years, in 
the UK, respectively9. Furthermore, osteopenia 
among 50-year adults in the US is predicted to 
increase from 43.4 million in 2010 to 52.0 mil-
lion in 2020 and 57.2 million in 203010. Despite 
the increasing prevalence and the advances in 
pharmacotherapy, the majority of patients with 
osteopenia and osteoporosis are not adequately 
treated, and follow-up scans at 2 years as well as 
adherence to therapy remain poor11. Taking into 
account the side effects associated with a long-
term use, drug treatment such as estrogen- or 
androgen-based therapies and bisphosphonates 
should be considered only for patients with 
osteoporosis and for patients with osteopenia at 
high risk of fractures7. On the other hand, osteo-
penic patients without such risk factors should 
be advised to adopt a “bone friendly” lifestyle 
including regular physical exercise, moderation 
in alcohol use, smoking cessation and nutritional 
modifications7. Actually, proper nutrition is one 
of the most important preventive methods for 
osteopenia; in addition to calcium and vitamin 
D12-14, adequate intake of other mineral elements 
(magnesium, phosphorus, copper, zinc, fluoride, 
sodium, potassium) and vitamins (vitamin K, vi-
tamin C, vitamins B) as well as carotenoids, have 
been associated with bone health15-18. Among 
nutritional supplements, curcumin is one of the 
most investigated because of its low toxicity 
and the broad range of molecular targets, lead-
ing to multiple pharmaceutical activities such 
as hepatoprotective, anti-inflammatory and an-
tioxidant properties19-25. Interestingly, in vitro 
and in vivo studies have associated curcumin 
with bone health, particularly with improved 
BMD and mechanical properties, suggesting 
potential applications of curcumin to treat bone 
disorders26,27. However clinical studies in human 
investigating curcumin’s effects on bone health 
are scant. To this end, we evaluated the efficacy, 
in term of changes in bone density, and safety 
of an oral formulation based on turmeric phy-
tosome (Meriva®, Indena SpA, Milan, Italy), in 
subjects suffering from low bone density. 
Patients and Methods
This was a registry, supplement study con-
ducted in 57 otherwise healthy subjects with low 
bone density (DXA t-score between -1 and -2.5). 
Supplement studies define the field of activity of 
pharma-standard supplements and their possible 
preventive, pre-therapeutic applications. “Supple-
ment human studies” produce supplementary data 
to be compared with those from the best available 
management plans. These types of researches are 
performed with products with high level of safety 
and pharmaceutical standards28-30. Informed par-
ticipants (n=57) freely decided to follow either a 
standard management (SM) to control low bone 
density (control group=28) or SM associated with 
oral daily supplementation (supplement group=29). 
Daily supplementation dosage consisted of 1 tablet 
of Meriva® (Indena SpA, Milan, Italy), containing 
1000 mg of the oral curcumin delivery form, for 6 
months. Standard management included a complete 
nutritional evaluation, supplying a diet with ade-
quate content of vitamins D, C and calcium; regular 
exercise program of 20 min at least 4 times/week 
including light weight lifting and walking or run-
ning according to patients’ preferences. All subjects 
were reasonably fit, with a body mass index <25.
By inclusion criteria, all routine blood tests, 
erythrocyte sedimentation rate and C-reactive pro-
tein were within the normal values. Hypertensive 
and hypercholesterolemic subjects were excluded. 
No drugs or other products were used during the 
observational registry period. In all subjects bone 
densities (measured considering the passage of an 
ultrasound beam through the bone and its possible 
attenuation) at the heel, small finger and upper jaw 
were evaluated at inclusion and at different time 
points during the observational period (4, 12 and 
24 weeks). The quantitative ultrasound measure-
ment of the calcaneus (heel bone) was performed 
by using Sahara clinical bone sonometer (Hologic 
Inc., Marlborough, MA, USA). The small finger 
and upper jaw density were evaluated by using a 
specific, high-resolution ultrasound scanner (Prei-
rus, Hitachi, Tokyo, Japan) with a defined elastoso-
nography setting measuring in a semi-quantitative 
way the grey scale median (GSM) of the imag-
es31 (Figure 1). Treatment tolerability and adverse 
events were also evaluated. 
A. Riva, S. Togni, L. Giacomelli, F. Franceschi, R. Eggenhoffner, et al.
1686
Statistical Analysis
Intragroup comparisons were performed by 
using ANOVA test with post-hoc Bonferroni cor-
rection. p-value <0.05 was considered significant.
Results 
Demographics details of the study population 
are shown in Table I. The supplemented group and 
the control group were comparable in term of age 
and gender distribution. Given that the attenuation 
of the ultrasound passage is related to absolute 
bone density, the bone density of the heel measured 
by the Sahara densitometer remarkably improved 
in the Meriva®-supplemented group (Table II). In 
particular, differently from the control group, the 
quantitative ultrasounds transmission of the calca-
neus significantly decreased at week 12 (-18.4%) 
and at week 24 (-21.0%), compared to baseline 
values, in subjects taking curcumin-based oral sup-
plementation (Figure 2). The GSM measurement in 
ultrasound images of small finger and upper jaw 
significantly increased during the study in sup-
plemented patients, reaching +7.1% and +4.8%, at 
week 24, respectively (Table II and Figure 3). In the 
control group no significant changes of GSM were 
observed. No safety and tolerability issues were 
observed during the observational period.
Discussion
Bone homeostasis is maintained by a bal-
ance between bone resorption by osteoclasts and 
bone formation by osteoblasts. In subjects with 
osteopenia, an excessive bone resorption or an 
inadequate bone formation during remodeling 
affect this balance, resulting in low bone den-
sity32. In particular, the underlying pathogenic 
mechanisms of low bone density and osteopo-
rosis also involve the ligand for the receptor 
Figure 1. Small finger ultrasound evaluation, distal phalanx. 
A, In the box, the area where the grey scale median (GSM) val-
ue was evaluated. B, Example of loss of bone density.
SD: standard deviation.
Table I. Details of subjects enrolled in the study.
 Standard Standard
 Management Management +
  Meriva®
Subjects (males) 28 (14) 29 (13)
Age, years  70.8±2.1 71.0±2.1
  (mean ± SD) 
Table II. Assessment of the bone density in the heel bone, small finger and upper jaw.
Data are expressed as mean (range). *p<0.05 vs. inclusion. 
       Standard Management   Standard Management + Meriva®
 Inclusion 4 weeks 12 weeks 24 weeks Inclusion 4 weeks 12 weeks 24 weeks
Heel bone 100 -4 -5.4 -6 100 -12.3 -18.4* -21.0*
  density, % 
Small finger  30.3 +1.2% +1.3% +1.3% 31.2  +5.3% +6.9%* +7.1%*
  bone density,  (13.0-36.0) (0.0-3.4)% (0.0-3.0)% (0.0-2.2)% (11.0-39.0) (0.0-8.4)%  (3.0-9.0)%  (4.1-9.0)% 
  GSM (range)
Upper jaw  32.7  +0.2% +0.3% +0.3% 33 +2.3% +3.8 %* +4.8%*
  bone density,  (10.0-43.0) (0-2)% (0.0-2.4)% (0.0-1.9)%  (12.0-38.0)  (1.0-7.7) % (2.0-7.6)% (2.2-6.9)%
  GSM (range)
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activator of NF-κB (RANK) namely RANKL, 
which is expressed by osteoblasts and interacts 
with RANK to activate differentiation of pro-
genitors into osteoclasts and maintain osteoclast 
function33. Recent in vitro and in vivo studies 
revealed that curcumin, the polyphenolic com-
pound derived from the Indian spice, turmeric 
(Curcuma longa), can target several molecular 
mechanisms related to bone homeostasis, includ-
ing the activation and differentiation of osteo-
clasts. Experiments performed on cell culture 
derived from long bone of rabbit demonstrated 
Figure 2. Changes (in per-
centage from initial values) 
in heel bone density.
Figure 3. Changes (in percentage from initial values) in small finger bone density.
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that curcumin inhibited osteoclastic bone resorp-
tion in a dose-dependent manner34. Also, Bharti 
et al35 demonstrated that curcumin suppresses 
RANKL pathways and osteoclastogenesis by in-
terfering with the NF-kB signaling. Translational 
research studies on postmenopausal osteoporosis 
models, the ovariectomizing (OVX) female rats, 
evaluating several bone parameters, gave mixed 
results36,37. However, although Folwarczna et al37 
did not observe any significant improvement of 
bone mineralization or mechanical properties in 
curcumin-treated OVX rats, they reported ben-
eficial effects in some bone histomorphomet-
ric parameters impaired by estrogen deficiency. 
Taken together, these observations suggest that 
curcumin administration could improve several 
aspects of bone health and may be helpful to al-
leviate bone disorders such as low bone density. 
In this registry study, a curcumin-based oral sup-
plementation quickly improved (improvements 
were observed after few weeks of treatment) 
bone health parameters such as bone density, in 
asymptomatic subjects with osteopenia. The ben-
eficial effects observed in Meriva®-supplemented 
subjects were associated with curcumin proper-
ties; standard management only produced mini-
mal changes. To the best of our knowledge, this 
represents the first study investigating the effects 
of curcumin on bone health, in humans. Further 
researches in larger and selected populations are 
needed. We suggest that in osteopenic, otherwise 
healthy subjects with BMI >25, supplementation 
with Meriva® could lead to even greater changes 
in bone density.
Conclusions
This preliminary study offers a new indica-
tion for the use of curcumin in combination with 
an appropriate lifestyle in the prevention and 
management of osteopenia in otherwise healthy 
subjects. 
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